Compare IVR & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IVR | ETON |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 625.3M | 510.1M |
| IPO Year | N/A | 2018 |
| Metric | IVR | ETON |
|---|---|---|
| Price | $8.08 | $20.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $8.25 | ★ $31.00 |
| AVG Volume (30 Days) | ★ 2.1M | 281.1K |
| Earning Date | 05-06-2026 | 03-19-2026 |
| Dividend Yield | ★ 17.78% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $39,011,000.00 |
| Revenue This Year | $150.63 | $107.23 |
| Revenue Next Year | N/A | $29.72 |
| P/E Ratio | $6.63 | ★ N/A |
| Revenue Growth | N/A | ★ 23.29 |
| 52 Week Low | $5.86 | $11.09 |
| 52 Week High | $9.50 | $23.00 |
| Indicator | IVR | ETON |
|---|---|---|
| Relative Strength Index (RSI) | 38.08 | 74.01 |
| Support Level | $7.94 | $16.09 |
| Resistance Level | $8.29 | $21.88 |
| Average True Range (ATR) | 0.20 | 1.01 |
| MACD | -0.01 | 0.20 |
| Stochastic Oscillator | 36.92 | 96.81 |
Invesco Mortgage Capital Inc is a REIT that invests, finances, and manages residential and commercial mortgage-backed securities and mortgage loans. The company's portfolio consists of residential mortgage-backed securities (RMBS) that are guaranteed by a U.S. government agency such as the Government National Mortgage Association, or a federally chartered corporation such as the Federal National Mortgage Association or the Federal Home Loan Mortgage Corporation; Commercial mortgage-backed securities (CMBS) that are not guaranteed by a U.S. government agency or a federally chartered corporation; RMBS that are not guaranteed by a U.S. government agency or a federally chartered corporation; and other real estate-related financing arrangements.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.